The war on cancer

Lancet

Volumn 347, Issue 9012, 1996, Pages 1377-1381

  Sporn, Michael B ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER; CANCER INVASION; CANCER MORTALITY; CANCER PREVENTION; CANCER STATISTICS; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHILDHOOD CANCER; HEALTH PROMOTION; HODGKIN DISEASE; HUMAN; LYMPHATIC LEUKEMIA; METASTASIS; ONCOLOGY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SHORT SURVEY; TESTIS CANCER;

EID: 0029870954     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91015-6     Document Type: Article

References (48)

1. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF. Recent cancer trends in the United States. J Natl Cancer Inst 1995; 87: 175-82.
2. Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK, eds. SEER cancer statistics review, 1973-1992, tables and graphs. Bethesda: Natonal Cancer Institute NIH pub no 95-2789: 1995.
3. Bailar JC, Smith EM. Progress against cancer? N Engl J Med 1986; 314: 1226-32.
4. Hermon C, Beral V. Breast cancer mortality rates are levelling off or beginning to decline in many western countries: analysis of time trends, age - cohort and age - period models of breast cancer mortality in 20 countries. Br J Cancer 1996; 73: 955-60.
5. Levi F, La Vecchia C, Lucchini F, Negri E. Worldwide trends in cancer mortality in the elderly, 1955-1992. Eur J Cancer 1996; 32A: 652-72.
6. Weinberg RA. Prospects for cancer genetics. Cancer Surv 1995; 25: 3-12.
7. Vogelstein B, Kinzler KW. Colorectal cancer and the intersection between basic and clinical research. Cold Spring Harbor Symp Quant Biol 1994; 59: 517-21.
8. Knudson AG. Mutation and cancer: a personal odyssey. Adv Cancer Res 1995; 67: 1-23.
9. Sporn MB, Roberts AB, eds. Peptide growth factors and their receptors I and II. New York: Springer-Verlag, 1990.
10. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-76.
11. Pierce GB, Shikes R, Fink LM. Cancer - a problem of developmental biology. Englewood Cliffs, NJ: Prentice Hall, 1978.
12. Mintz B, Fleischman RA. Teratocarcinomas and other neoplasms as developmental defects in gene expression. Adv Cancer Res 1981; 34: 211-78.
13. Friend C, Scher W, Holland JG, Sato T. Hemoglobin synthesis in murine virus induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA 1971; 68: 378-82.
14. Sachs L. Control of normal cell differentation and the phenotypic reversion of malignancy in myeloid leukemia cells. Nature 1978; 274: 535-39.
15. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980; 77: 2936-40.
16. Huang ME, Ye YC, Chen SR, et al. Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72.
17. Symposium on early lesions and the development of epithelial cancer. Cancer Res 1976; 36: 2475-706.
18. Sporn MB. Carcinogenesis and cancer: different perspectives on the same disease. Cancer Res 1991; 51: 6215-18.
19. Boone CW, Kelloff GJ, Steele VE. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res 1992; 52: 1651-59.
20. Farber E. Cell proliferation as a major risk for cancer: a concept of doubtful validity. Cancer Res 1995; 55: 3759-62.
21. Foulds L. Neoplastic development. New York: Academic Press, 1969.
22. Farber E, Rubin H. Cellular adaptation in the origin and development of cancer. Cancer Res 1991; 51: 2751-61.
23. Clark WH. The nature of cancer: morphogenesis and progressive (self)-disorganization in neoplastic development and progression. Acta Oncol 1995; 34: 3-21.
24. Sporn MB, Roberts AB. Role of retinoids in differentiation and carcinogenesis. Cancer Res 1983; 43: 3034-40.
25. Chen C, Parangi S, Tolentino MJ, Folkman J. A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 1995; 55: 4230-33.
26. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893-95.
27. Poste G, Greig R. On the genesis and regulation of cellular heterogeneity in malignant tumors. Invasion Metastasis 1982; 2: 137-76.
28. Mitelman F, Johansson B, Mertens F. Catalog of chromosome aberrations in cancer. 5th ed. New York: Wiley-Liss, 1994.
29. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372: 143-49.
30. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780-86.
31. Smith GA, Henderson IC. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology 1995. Philadelphia: Lippincott, 1995: 201-14.
32. Smith MA, McCaffrey RP, Karp JE. The secondary leukemias: challenges and research directions. J Natl Cancer Inst 1996; 88: 407-18.
33. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334: 745-51.
34. Li FP. Phenotypes, genotypes, and interventions for hereditary cancers. Cancer Epidemiol Biomark Prev 1995; 4: 579-82.
35. Collins FS. BRCA1 - lots of mutations, lots of dilemmas. N Engl J Med 1996; 334: 186-88.
36. Greenwald P, Kelloff G, Burch-Whitman C, Kramer BS. Chemoprevention. CA Cancer J Clin 1995; 45: 31-49.
37. Wartenberg LW. Prevention - therapy - basic science and the resolution of the cancer problem: presidential address. Cancer Res 1993; 53: 5890-96.
38. Sporn MB, Lippman SM. Chemoprevention of cancer. In: Holland JF, Frei E, Bast R, Kufe D, Morton D, Weichselbaum R, eds. Cancer Medicine. 4th ed. Baltimore: Williams & Wilkins (in press).
39. Hong WK, Lippman SM, Hittleman WN, Lotan R. Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Clin Cancer Res 1995; 1: 677-86.
40. Costa A, Decensi A, De Palo G, Veronesi U. Breast cancer chemoprevention with retinoids and tamoxifen. Proc Am Assoc Cancer Res 1996; 37: 655-56.
41. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
42. Jordan VC, ed. Long-term tamosifen treatment for breast cancer. Madison: University of Wisconsin Press, 1994.
43. Jordan VC, Assikis AJ. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res 1995; 1: 467-72.
44. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholsterolemia. N Engl J Med 1995; 333: 1301-07.
45. Pedersen TR. Lowering cholesterol with drugs and diet. N Engl J Med 1995; 333: 1350-51.
46. Cutler JA, Psaty BM, MacMahon S, Furburg CD. Public health issues in hypertension control: what has been learned from clinical trials. In; Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press, 1995: 253-70.
47. Sporn MB. Combination chemoprevention of cancer. Nature 1980; 280: 107-08.
48. Koop CE. A personal role in health care reform. Am J Publ Health 1995; 85: 759-60.